DUBLIN, Ireland--(BUSINESS WIRE)--Elan Corporation, plc (NYSE:ELN) today announced its third quarter 2006 financial results. Commenting on Elan’s business, Kelly Martin, Elan’s president and chief executive officer, said, “The third quarter provided further evidence of progress in key areas. We are encouraged by the initial results in the relaunch of Tysabri for MS in the U.S. market and the launch in the European markets. As patients and physicians seek greater efficacy and therapeutic options for combating the degenerative nature of this disease, we remain confident that Tysabri will play a significant role in the treatment of MS moving forward. We plan to file for Crohn’s in the U.S. by the end of this year. In our scientific pipeline, we recently announced a new collaboration in the area of Alzheimer’s with Transition Therapeutics and are working together to advance this Phase 1 small molecule program. We are pleased to report that we have started dosing patients with ELND-001, an oral compound from our autoimmune program.”
